# Vinblastine for Leukoreduction in Newly Diagnosed AML and Hyperleukocytosis

> **NCT05062278** · PHASE2 · UNKNOWN · sponsor: **Hospital Universitario Dr. Jose E. Gonzalez** · enrollment: 46 (estimated)

## Conditions studied

- AML
- Hyperleukocytosis

## Interventions

- **DRUG:** Vinblastine
- **DRUG:** Hydroxyurea capsules

## Key facts

- **NCT ID:** NCT05062278
- **Lead sponsor:** Hospital Universitario Dr. Jose E. Gonzalez
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-26
- **Primary completion:** 2025-07-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2021-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05062278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05062278, "Vinblastine for Leukoreduction in Newly Diagnosed AML and Hyperleukocytosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05062278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*